3 restraining orders placed on ZymoGenetics regarding Recothrom
A federal court in Tennessee granted three temporary restraining orders against ZymoGenetics, preventing it from marketing Recothrom, a drug used to control hemorrhage. The orders came after King Pharmaceuticals and three other firms filed a lawsuit accusing ZymoGenetics of unfair competition and false advertising, among other claims. In a regulatory filing, the biotech firm denied wrongdoing and said it plans to "vigorously defend" itself against the allegations.
American City Business Journals
| 11/4
This story published in BIO SmartBrief on 11/05/2009
|
BIO SmartBrief
Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more |
|